» Articles » PMID: 33751108

MiR-15a/16-1 Deletion in Activated B Cells Promotes Plasma Cell and Mature B-cell Neoplasms

Abstract

Chromosome 13q deletion [del(13q)], harboring the miR-15a/16-1 cluster, is one of the most common genetic alterations in mature B-cell malignancies, which originate from germinal center (GC) and post-GC B cells. Moreover, miR-15a/16 expression is frequently reduced in lymphoma and multiple myeloma (MM) cells without del(13q), suggesting important tumor-suppressor activity. However, the role of miR-15a/16-1 in B-cell activation and initiation of mature B-cell neoplasms remains to be determined. We show that conditional deletion of the miR-15a/16-1 cluster in murine GC B cells induces moderate but widespread molecular and functional changes including an increased number of GC B cells, percentage of dark zone B cells, and maturation into plasma cells. With time, this leads to development of mature B-cell neoplasms resembling human extramedullary plasmacytoma (EP) as well as follicular and diffuse large B-cell lymphomas. The indolent nature and lack of bone marrow involvement of EP in our murine model resembles human primary EP rather than MM that has progressed to extramedullary disease. We corroborate human primary EP having low levels of miR-15a/16 expression, with del(13q) being the most common genetic loss. Additionally, we show that, although the mutational profile of human EP is similar to MM, there are some exceptions such as the low frequency of hyperdiploidy in EP, which could account for different disease presentation. Taken together, our studies highlight the significant role of the miR-15a/16-1 cluster in the regulation of the GC reaction and its fundamental context-dependent tumor-suppression function in plasma cell and B-cell malignancies.

Citing Articles

BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.

Lee H, Haque S, Gupta R, Kolitz J, Allen S, Rai K Lymphatics. 2024; 2(2):50-78.

PMID: 39664277 PMC: 11632909. DOI: 10.3390/lymphatics2020005.


DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

Liu L, Gong D, Sun H, Feng F, Xu J, Sun X Front Immunol. 2024; 15:1470328.

PMID: 39380995 PMC: 11459316. DOI: 10.3389/fimmu.2024.1470328.


Potential Use of MicroRNA Technology in Thalassemia Therapy.

Rujito L, Wardana T, Siswandari W, Nainggolan I, Sasongko T J Clin Med Res. 2024; 16(9):411-422.

PMID: 39346566 PMC: 11426174. DOI: 10.14740/jocmr5245.


The marine-derived compound TAG alleviates Parkinson's disease by restoring RUBCN-mediated lipid metabolism homeostasis.

Yang P, Liu Y, Tong Z, Huang Q, Xie X, Mao S Acta Pharmacol Sin. 2024; 45(7):1366-1380.

PMID: 38538717 PMC: 11192910. DOI: 10.1038/s41401-024-01259-y.


MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.

Ali A, Mahla S, Reza V, Hossein A, Bahareh K, Mohammad H EJHaem. 2024; 5(1):191-205.

PMID: 38406506 PMC: 10887358. DOI: 10.1002/jha2.849.


References
1.
Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

2.
Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson P . Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019; 9(4):39. PMC: 6435669. DOI: 10.1038/s41408-019-0199-3. View

3.
Rossi M, Botta C, Arbitrio M, Grembiale R, Tagliaferri P, Tassone P . Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget. 2018; 9(28):20119-20133. PMC: 5929451. DOI: 10.18632/oncotarget.24614. View

4.
Chesi M, Stein C, Garbitt V, Sharik M, Asmann Y, Bergsagel M . Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020; 1(1):68-81. PMC: 7494232. DOI: 10.1158/0008-5472.BCD-19-0068. View

5.
Koralov S, Muljo S, Galler G, Krek A, Chakraborty T, Kanellopoulou C . Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008; 132(5):860-74. DOI: 10.1016/j.cell.2008.02.020. View